AU4499697A - Method for treating parasitic diseases with proteasome inhibitors - Google Patents

Method for treating parasitic diseases with proteasome inhibitors

Info

Publication number
AU4499697A
AU4499697A AU44996/97A AU4499697A AU4499697A AU 4499697 A AU4499697 A AU 4499697A AU 44996/97 A AU44996/97 A AU 44996/97A AU 4499697 A AU4499697 A AU 4499697A AU 4499697 A AU4499697 A AU 4499697A
Authority
AU
Australia
Prior art keywords
proteasome inhibitors
parasitic diseases
treating parasitic
treating
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU44996/97A
Inventor
Daniel Eichinger
Jorge Gonzales
Victor Nussenzweig
Photini Sinnis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Publication of AU4499697A publication Critical patent/AU4499697A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU44996/97A 1996-09-13 1997-09-12 Method for treating parasitic diseases with proteasome inhibitors Abandoned AU4499697A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2589496P 1996-09-13 1996-09-13
US60025894 1996-09-13
PCT/US1997/017136 WO1998010779A1 (en) 1996-09-13 1997-09-12 Method for treating parasitic diseases with proteasome inhibitors

Publications (1)

Publication Number Publication Date
AU4499697A true AU4499697A (en) 1998-04-02

Family

ID=21828635

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44996/97A Abandoned AU4499697A (en) 1996-09-13 1997-09-12 Method for treating parasitic diseases with proteasome inhibitors

Country Status (2)

Country Link
AU (1) AU4499697A (en)
WO (1) WO1998010779A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
PT1745064E (en) 2004-04-15 2011-03-23 Proteolix Inc Compounds for proteasome enzyme inhibition
JP5108509B2 (en) 2004-05-10 2012-12-26 プロテオリックス， インコーポレイテッド Compounds for enzyme inhibition
EP1805208A2 (en) 2004-10-20 2007-07-11 Proteolix, Inc. Labeled compounds for proteasome inhibition
HUE027850T2 (en) 2004-12-07 2016-11-28 Onyx Therapeutics Inc Composition for proteasome inhibition
ATE483725T1 (en) 2005-05-27 2010-10-15 Proteolix Inc SUBSTRATE FOR RPN-11 ENZYM ACTIVITY
DK2623113T3 (en) 2005-11-09 2017-07-17 Onyx Therapeutics Inc Enzyme inhibition compound
US7691852B2 (en) 2006-06-19 2010-04-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
DK2207791T4 (en) 2007-10-04 2019-10-07 Onyx Therapeutics Inc CRYSTALLINIC PEPTIDE POXYKETON PROTEASE INHIBITORS AND SYNTHESIS OF AMINO ACID EPOXIDES
ES2617560T3 (en) 2008-10-21 2017-06-19 Onyx Therapeutics, Inc. Combination of the carfilzomib peptide epoxy ketone proteasome inhibitor with melphalan for use in the treatment of multiple myeloma
TWI504598B (en) 2009-03-20 2015-10-21 Onyx Therapeutics Inc Crystalline tripeptide epoxy ketone protease inhibitors
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
MA34133B1 (en) 2010-03-01 2013-04-03 Onyx Therapeutics Inc COMPOUNDS FOR INHIBITORS OF IMMUNOPROTEASOME
EA033614B1 (en) 2012-05-08 2019-11-11 Onyx Therapeutics Inc Cylodextrin complexation methods for formulating peptide proteasome inhibitors
EP2869820A4 (en) 2012-07-09 2016-02-17 Onyx Therapeutics Inc Prodrugs of peptide epoxy ketone protease inhibitors
US10022326B2 (en) 2012-07-18 2018-07-17 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
BR112015001213A2 (en) 2012-07-20 2018-05-22 Cleave Biosciences Inc fused pyrimidines as p97 complex inhibitors
WO2014066506A2 (en) 2012-10-23 2014-05-01 Cleave Biosciences, Inc. Compositions and methods for jamm protein inhibition
TW201422255A (en) 2012-10-24 2014-06-16 Onyx Therapeutics Inc Modified release formulations for oprozomib
EA030957B1 (en) 2013-03-14 2018-10-31 Оникс Терапьютикс, Инк. Dipeptide and tripeptide epoxy ketone protease inhibitors
AR095426A1 (en) 2013-03-14 2015-10-14 Onyx Therapeutics Inc TRIPEPTIDE INHIBITORS OF PROTEASA EPOXYCETONE
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
EP3080101A1 (en) 2013-12-10 2016-10-19 Cleave Biosciences, Inc. Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex
BR112016014004B1 (en) * 2013-12-19 2022-11-01 Novartis Ag COMPOUNDS FOR THE TREATMENT OF PARASITIC DISEASES, THEIR USES, AND PHARMACEUTICAL COMPOSITIONS
ES2819867T3 (en) 2014-01-20 2021-04-19 Cleave Biosciences Inc Condensed pyrimidines as inhibitors of the p97 complex
MX2018016387A (en) 2016-06-29 2019-09-09 Kezar Life Sciences Crystalline salts of peptide epoxyketone immunoproteasome inhibitor.
AR108919A1 (en) 2016-06-29 2018-10-10 Kezar Life Sciences PREPARATION PROCESS OF THE EPOXYCETONE IMMUNOPROTEASOMA INHIBITOR, AND ITS PRECURSORS
US20180078532A1 (en) 2016-09-21 2018-03-22 Amgen Inc. Immediate release formulations for oprozomib
US20180161279A1 (en) 2016-12-14 2018-06-14 Amgen Inc. Gastro-retentive modified release dosage forms for oprozomib and process to make thereof
JP2023510258A (en) 2020-01-10 2023-03-13 アムジエン・インコーポレーテツド Stable cyclodextrin-free carfilzomib formulation
JP2023509518A (en) 2020-01-10 2023-03-08 アムジエン・インコーポレーテツド Stable Cyclodextrin-Free Carfilzomib Formulation

Also Published As

Publication number Publication date
WO1998010779A1 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
AU4499697A (en) Method for treating parasitic diseases with proteasome inhibitors
AU2543097A (en) Method for treating pain
AU2587297A (en) Method for treating pain
AU9035498A (en) Method for treating pain
AU5382099A (en) Apparatus and methods for radiotherapy
AU5268696A (en) Novel compounds and methods for therapy
AU3146495A (en) Methods for stereotactic implantation
AU4678399A (en) System and method for refining search queries
AU2091101A (en) Method and system for database query
AU7568698A (en) Method and apparatus for dermatology treatment
AU1527897A (en) Method for treating the prostate
AU8903798A (en) Method and apparatus for tissue remodeling
AU3556297A (en) Database apparatus
AU7383398A (en) Therapeutic glasses and method for using the same
AU7534100A (en) Apparatus for and method of searching
AU3825097A (en) Method for tightening skin
AU2808997A (en) Method for treating inflammation
AU5965396A (en) Method for rapid enzymatic alcohol removal
AU5362598A (en) Method for improving wastewater treatment
AU6198299A (en) Device and method for sterilising screwcaps
AU2340897A (en) Method for treating pain
AU2931695A (en) Method for forming soles and device therefor
AU5733099A (en) Method for treating ocular neovascular diseases
AU1337099A (en) Method for identifying micro-organisms
AU2584597A (en) Method for treating migraine pain